WO1994004658A1 - Methods for maturing precursor b cells - Google Patents
Methods for maturing precursor b cells Download PDFInfo
- Publication number
- WO1994004658A1 WO1994004658A1 PCT/US1993/007644 US9307644W WO9404658A1 WO 1994004658 A1 WO1994004658 A1 WO 1994004658A1 US 9307644 W US9307644 W US 9307644W WO 9404658 A1 WO9404658 A1 WO 9404658A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- activated
- precursor
- cell
- mature
- Prior art date
Links
- 210000001948 pro-b lymphocyte Anatomy 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims abstract description 68
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 32
- 108010002586 Interleukin-7 Proteins 0.000 claims abstract description 24
- 230000003248 secreting effect Effects 0.000 claims abstract description 20
- 230000001404 mediated effect Effects 0.000 claims abstract description 15
- 230000004069 differentiation Effects 0.000 claims abstract description 14
- 239000012736 aqueous medium Substances 0.000 claims abstract description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 8
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 49
- 239000012528 membrane Substances 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 41
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 32
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 32
- 102000004388 Interleukin-4 Human genes 0.000 description 26
- 210000001185 bone marrow Anatomy 0.000 description 22
- 102000000704 Interleukin-7 Human genes 0.000 description 20
- 210000003519 mature b lymphocyte Anatomy 0.000 description 15
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 230000024245 cell differentiation Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000004976 peripheral blood cell Anatomy 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241001307210 Pene Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 201000008162 B cell deficiency Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 244000000015 environmental pathogen Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Definitions
- the present invention relates to the development and differentiation of cells in a mammalian immune system. More particularly, the invention provides culture conditions for the in vitro maturation of precursor B cells. This is a valuable invention because it defines a method to induce development of antibody producing mature B-cells from early precursor cells.
- the present invention fills this need by providing for an in vitro method of inducing differentiation of precursor B cells (pre-B cells) to mature Immunoglobulin (Ig) -secreting B cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4 and a contact mediated signal provided by optimally activated CD4 + T cells.
- the contact mediated signal is generally provided by incubating optimally activated CD4 + T cells, i.e., CD4+ T cells which have been activated for from 2-3 days, with the precursor B cells and the IL-4.
- the contact mediated signal can also be provided by cell membranes from optimally activated CD4 + T cells.
- the medium may also contain IL-7.
- the present invention further provides for an in vitro method of inducing differentiation of precursor B cells (pre-B cells) to mature Immunoglobulin (Ig) -secreting B cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4, IL-7 and a contact mediated signal provided by non-optimally activated CD4 + T cells.
- a non-optimally activated CD4 + T cell is a CD4 + T cell which has been activated for from 4-6 days.
- the resulting mature B cells may be introduced into a host and in certain embodiments may be derived from the same host.
- the present invention further provides for methods of reconstituting an impaired immune system of a human comprising the steps of: (a) isolating precursor B cells from a human; (b) maturing the precursor B cells to maturity by contacting the precursor B cells in an aqueous medium with an amount of IL-4 and contact mediated signal provided by optimally activated CD4 + T cells or membranes from an optimally activated CD4 + T cell effective to mature the precursor B cells; and (c) administering the mature B cells of step (b) to a human.
- IL-7 is added to the aqueous medium so as to produce mature Ig-secrering B cells.
- the present invention further provides for in vivo methods of maturing precursor B cells in mammals by administering an effective amount of IL-4 and IL-7 sufficient to mature precursor B cells into mature B cells.
- the preferred mode involves human IL-4 and human and IL-7.
- the present invention also provides a biological screening method to define the co-stimulating components needed to support growth and differentiation of early precursor B cells.
- the present invention has allowed identification of the importance of activated CD4 + T cells or their membranes, in human B cell development. This in vitro assay can also be used to identify the factors and genes encoding co-stimulatory components.
- the invention further discloses the therapeutic utility of IL-7 when combined with IL-4 for the in vivo maturation of pre-B cells.
- Deficient humoral immunity is a problem in a number of situations, such as after bone marrow [BM] transplantation and in newborns, especially premature newborns, whose major cause of death are bacterial infections.
- BM bone marrow
- agammaglobulinemias due to genetic defects can cause life long susceptibility to infections.
- the clinical use of IL-4 and IL-7 are disclosed.
- Mature resting B cells differentiate into Immunoglobulin [Ig] secreting cells and undergo Ig isotype switching in response to surface IgM [slgM] mediated signals in the presence of a contact mediated signal which is provided by CD4 + T cells via soluble and membrane bound factors.
- Cytokines are thought essential in B cell proliferation and differentiation, as well as in isotype switching. Under in vitro conditions, IL-4 is known to induce IgG4 and IgE switching, but additional signals provided by CD4 + T cells are required.
- cytokines such as IL-6, tumor necrosis factor (TNF)- ⁇ , TGF- ⁇ , IFN- ⁇ , and IFN- ⁇ , are known to modulate IL-4-induced IgE synthesis in mature B cells. TGF- ⁇ also induces IgA switching.
- murine pre-B cells were shown to undergo isotype switching and to differentiate into Ig secreting plasma cells when co-cultured with dendritic cells and activated T cells [Spalding & Griffen, Cell 44: 507-515 (1986)].
- these culture systems have not been successful when human pre-B cells are studied.
- Pre-B cells are classically characterized by lack of surface IgM (slgM”) expression.
- Human pre-B cells were recently shown to spontaneously differentiate into IgM + cells when cultured in RPMI + 10% fetal calf serum in the absence of exogenous growth factors or cytokines, but no differentiation into Ig-secreting cells in these cultures was detected [Villablanca et al. ⁇ . Exp. Med. 172: 325-334 (1990)].
- the present invention provides culture conditions permitting maturation of human pre-B cells.
- the work demonstrates that significant production of IgM, total IgG, IgG4 and IgE is detected when highly purified human slgM", CD19 + pre-B cells are co-cultured with optimally activated cloned CD4 + T cells in the presence of IL-4.
- An optimally activated CD4 + T cell is a CD4 + T cell which is able to produce a contact mediated signal needed for human slgM", CD19+ pre-B cells to develop into mature Ig secreting B cells in the presence of IL-4.
- the CD4 + T cells which are used are obtained 2-3 days after activation.
- CD4 + T cells When CD4 + T cells are used 4-6 days after activation, no Ig synthesis by the B cells is observed. However, if IL-7 is added to a culture containing IL-4 and CD4 + T cells which have been obtained 4-6 days after activation, the human slgM", CD19 + pre-B cells do develop into Ig secreting mature B cells. This is distinguished from earlier work (Punnonen et al, 1992, supra) which disclosed that sIgM + fetal BM B cells underwent isotype switching and differentiation into Ig secreting cells in response to CD4 + T cells and IL-4 without IL-7.
- Membrane preparations of activated CD4 + T cell clones will also induce IgM and IgG synthesis by pre-B cells in the presence of IL-4 indicating that the co-stimulatory signal required in pre-B cell differentiation is in a membrane-bound form.
- Precursor B cells are surface IgM" and CD19 + .
- Classical definition of pre-B cells is that they have IgM in their cytoplasm ( ⁇ ).
- mature B cells are defined as expressing surface IgM and CD19".
- Pre-B cells can be obtained from bone marrow of either adults or fetuses.
- pre-B cells are obtained from mammalian, e.g. human, bone marrow (BM).
- BM bone marrow
- the marrow cells are extracted from the mammalian source using conventional techniques. These include extraction by needle or by surgical removal of bone material.
- the marrow cells are diluted with physiologically compatible buffer containing nutrients.
- Diluents include phosphate buffered saline (PBS) and RPMI-1640 from JRH Biosciences, Lenexa, KS which is preferred.
- PBS phosphate buffered saline
- RPMI-1640 from JRH Biosciences, Lenexa, KS which is preferred.
- the cells are repeatedly washed using low speed centrifugation. Red blood cells are lysed by osmotic shock using a hypotonic buffer solution.
- a preferred buffer and conditions are Tris- buffered 0.83% NH4CI (pH 7.2) at room temperature for two minutes, after which the cells are washed twice.
- the intact cells are finally counted and resuspended in Yssel's medium [Yssel et al. ⁇ . Immunol. Methods, 72: 219 (1984)] supplemented with 10% fetal calf serum (FCS).
- Iscove's modified Dulbecco's Medium (IMDM (JRH Biosciences 51-47178, 500 ml) (w/1-glutamine, w/25 mM HEPES, w/ Alpha thioglycerol).
- Bovine serum albumin (Sigma, A2153 or ⁇ 0.1ng/mg endotoxin detectable (Sigma A3675) to final concentration of 0.25% (w/v).
- Oleic acid Sigma 03879 to final concentration of 2 ⁇ g/ml (Stock linoleic and oleic acid should be stored at -20°C under nitrogen to prevent oxidation of the unsarurated bond; make glass ampoules containing 5 mg of linoleic & 5 mg of oleic acid. For each preparation, dissolve the fatty acids in ethanol (100 ⁇ l) and add this mixture to the medium.
- Palmitic acid (Sigma P-5917) to final concentration of 2 ⁇ g/ml [stock of palmitic acid in ethanol (20 mg/ml) and add the right concentration] (store at 4°C).
- Penicillin / streptomycin (TRH cat. nr. 59-60277P, 100 ml) 5 ml in 500 ml.
- the pre-B cells are obtained.
- the pre-B cells are isolated by monoclonal antibodies specific for pre-B cells.
- the desired slgM", CD19 + pre-B cells are then sorted using a fluorescence activated cell sorter (FACS) or magnetic beads according to standard procedures.
- FACS fluorescence activated cell sorter
- the pre-B cells may be crudely enriched using a ficoll density gradient where the pre-B cells are separated from red blood cells and granulocytes on a density gradient (1.077 gm/ml) spun at 800 x g for 20 minutes. The pre-B cells will be found at the interface.
- the pre-B cells do not carry the following epitope markers CD3, CD4, CD8, CD14, CD33 or slgM.
- the desired pre-B cells can be isolated from undesired cells.
- the pre-B cells are isolated from the heterogeneous population of bone marrow cells using immunoaffinity methods which specifically target unique pre-B cell surface epitopes.
- epitopes include CD19 and CD10.
- the pre-B cells are cultured in the presence of optimally activated CD4 + T cells or membranes obtained from the activated T cells.
- CD4 + T cells are cloned from activated mammalian (human) peripheral blood cells (PBC).
- peripheral blood cells are obtained from standard blood drawing techniques.
- the cells are then activated by mitogenic lectins such as phytohemagglutinin (PHA), Concanavalin A (Con A), soluble antigens such as tetanus toxoid, alloantigens expressed in allogenic PBC, or Epstein Barr Virus (EBV) transformed in B cells.
- mitogenic lectins such as phytohemagglutinin (PHA), Concanavalin A (Con A), soluble antigens such as tetanus toxoid, alloantigens expressed in allogenic PBC, or Epstein Barr Virus (EBV) transformed in B cells.
- PHA phytohemagglutinin
- Con A Concanavalin A
- soluble antigens such as tetanus toxoid
- IL-7 can also be added to enhance differentiation of the pre-B cells into Ig-secreting cells.
- CD4 + T cells are not optimally activated, i.e., they have been activated for more than 4 days, then IL-7 must be added to the culture medium in order for the pre-B cells to differentiate into Ig-secreting cells.
- Both cytokines are available through conventional recombinant expression systems.
- a suitable expression system for IL-4 is described in U.S. Pat. No. 5,017,691. The cloning and expression of IL-7 has been described by Goodwin
- cytokines can be purchased from commercial vendors such as R & D Systems, Inc. Minneapolis, MN.
- Maturation of the B cells can be monitored using a number of standard procedures. For example, one can measure the production of IgM, IgG, IgG4, IgE, or IgA using enzyme immunoassays. In brief, these methods involve standard immunoassays for the secretion of the several Ig classes known to be produced by mature B cells. Alternatively, surface molecules may be detected using analytical FACS methods.
- the in vitro maturation of pre-B cells permits the re-infusion into a patient, preferably the same patient from which the pre-B cells originated.
- the cells are harvested from the nutrient medium and resuspended into a physiologically compatible medium such as standard isotonic infusion fluids.
- the cells are then re-infused directly into the patient using conventional intravenous equipment.
- Procedures follow those for autologous bone marrow transplantation, e.g., reviewed in Bombik, B.M., Strategy of Autologous Bone Marrow Transplantation, in Autologous Bone Marrow Transplantation and Solid Tumors, J.G. McVie, O. Dalesio and IE. Smith, eds., pp. 13-18 (1984); and Autologous Bone Marrow Transplantation, Dickey, Spitzer, and Jagannath (Eds.), The University of Texas, M.D. Anderson Hospital and Tumor Institute at Houston (1987).
- the total number of mature B cells are preferably between 1-8 x 10 6 cells per kilogram of weight.
- the total liquid being infused should be between .75 and 1.5 liters for a mammal of 70 kg.
- Infusion of the entire mixture is typically carried out via a central venous catheter.
- the patient may receive supplemental therapy with a pharmaceutical preparation comprising the selected antibiotics.
- Pre-B cells represent approximately 1% of the cells in adult BM. Typically, no more than
- 5 x 10 8 cells can be isolated from a standard BM sample. By growing the pre-B cells under present culture conditions the cells can be increased 3 to 6 fold after 7 days. Thus, 3 x 10 9 cells will be available for infusion from a single BM aspiration. The level of antibody production and/or B cell numbers are monitored in order to re-administer additional B cells as necessary.
- IL-4 and IL-7 there are patients which have a B cell deficiency who will benefit from the co-administration of IL-4 and IL-7.
- Such patients include those with hypogammaglobulinemias, newborns, patients after BM transplantations, or cancer after heavy chemo- or radiation therapy. Both cytokines are co-administered to these patients either simultaneously or in succession.
- a dosage range of about 0.5 to about 10 and preferably 1 to 5 ⁇ g/kg body weight of both IL-4 and IL-7 is co- administered on a daily basis until the level of B cells approaches normal.
- the present invention can be illustrated by the following, non- limiting Examples. Unless otherwise specified, percentages given below for solids in solid mixtures, liquids in liquids, and solids in liquids are on a wt/wt, vol/vol and wt/vol basis, respectively.
- IL-4 Purified human recombinant IL-4 was provided by Schering-Plough Research (Kenilworth, NJ). Recombinant IL-7 was obtained from R & D Systems Inc. (Minneapolis, MN). Phycoerythrine (PE)-conjugated mAbs against CD19 as well as isotype control antibodies with irrelevant specifications, were obtained from Becton Dickinson (Mountain View, CA). FITC-conjugated anti-IgM mAb was obtained from Nordic Immunological Laboratories (Tilburg, the Netherlands).
- PE Phycoerythrine
- BM samples Human fetal bone marrow (BM) samples were obtained from fetuses varying from 16 to 24 weeks of gestation.
- BM cells were obtained by flushing RPMI-1640 0RH Biosciences, Lenexa, KS) with a syringe into the intramedullary cavities of the long bones. The cells were washed twice. Red blood cells were lysed by exposure to 2 ml of Tris-buffered 0.83% NH 4 CI (pH 7.2) at room temperature for two minutes, after which the cells were washed twice. The cells were finally counted and resuspended in Yssel's medium [Yssel et al. ⁇ . Immunol. Methods, 72 : 219 (1984)] supplemented with 10% fetal calf serum [FCS].
- FCS 10% fetal calf serum
- B cell precursors were obtained from fetal BM using fluorescence- activated cell sorter, FACStar Plus® (Becton Dickinson).
- BM cells were first incubated with CD19-PE and slgM-FITC for 30 min at 4°C.
- FTTC- and PE-conjugated mAb with irrelevant specificities were used as negative controls.
- the cells were washed twice with PBS.
- Cells with the light scatter characteristics of lymphocytes were gated and the cells were sorted on the basis of fluorescence stainings. Re-analysis of the sorted cells indicated 97-100% purities.
- the cells obtained were cultured in round-bottomed 96-well plates (Linbro, McLean, VA; Cat. No. 76-013-05) at 37°C in a humidified atmosphere containing 5% CO2 in 0.2 ml Yssel's medium supplemented with 10% FCS.
- the cells were cultured at a concentration of 5000 cells/well. All cultures were performed in triplicate.
- the human CD4 + T cell clone B21 [Roncarolo et al, f. Exp. Med. 167 : 1523 (1988) and Vieira et. al, Proc. Natl. Acad. Sci, U.S.A.
- IgM, total IgG, IgA and IgE secretion were determined by ELISA as described previously by Pene et al, Proc. Natl. Acad. Sci, U.S.A. 85 : 8166- 8170 (1988) and Pene et al, ⁇ . Immunol. 141 : 1218-1224 (1988).
- IgG4 secretion was determined by ELISA as described by Punnonen et al, J. Immunology, 148 : 3398-3404 (1992).
- the sensitivities of IgM, total IgG, and IgA ELISAs were 0.5-1 ng/ml, and the sensitivities of IgG4 and IgE ELISAs were 0.2 ng/ml.
- the highly purified pre-B cells were co-cultured in the presence of activated CD4 + T cells, IL-4 and/or IL-7. Significant production of IgM, total IgG, IgG4, and IgE in pre-B cell cultures was detected. Kinetic studies indicated that detectable levels of IgM and IgG in the supernatants of these cultures appeared at day 7, while IgE was detected at day 10.
- IL-7 was a specific requirement together with IL-4 of pre-B cells for maturation.
- the T cells were used 2-3 days after activation, they were competent to mature the pre-B cells with only the addition of IL-4 and without the addition of IL-7.
- Ig production in pre-B cell cultures was detected at cell numbers as low as 100 B cells/well. Because Ig production was detected using such low pre-B cell numbers, and no slgM "1" cells among sorted slgM" pre-B cells could be detected by FACS- analysis, the possibility of contaminating sIgM + B cells as the cause of Ig synthesis in our pre-B cell cultures can be excluded.
- a CD4 + T cell clone was activated for two days by ConA, and the cells were disrupted and membrane preparations were prepared as described by Gascan et al, Eur. f. Immunol, 22 : 1133-1141(1992).
- the data indicate that these membrane preparations of CD4 + T cells induced IgM and IgG synthesis by pre-B cells in the presence of IL-4, indicating that the co-stimulatory signal required in pre-B cell differentiations, indeed, is in a membrane-bound form. This implies that the present culture system also can be used as a screening method to identify T-cell membrane associated molecules and the genes encoding these molecules.
- an infusion of self-mature B cells is therapeutically beneficial.
- a bone marrow extract is obtained from the patient by aspiration.
- Pre-B cells are isolated from the marrow using the antibodies and cell sorting procedures provided in Example 1.
- the purified pre-B cells are then cultured and matured to antibody producing B cells according to the methods of Example 1.
- Mature antibody producing B cells are then harvested, suspended in physiological saline solution and re-infused. The number of circulating mature B cells and antibody production are then monitored using conventional techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides for a method of inducing differentiation of precursor B cells to immunoglobulin (Ig)-secreting cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4 and a contact mediated signal provided by optimally activated CD4+ cells. The present invention further provides for a method of inducing differentiation of precursor B cells to immunoglobulin (Ig)-secreting cells comprising contacting said percursor B cells with an aqueous medium comprised of IL-4, IL-7 and a contact mediated signal provided by non-optimally activated CD4+ cells.
Description
M E T H O D S F O R M A T U R I N G P R E C U R S O R B C E L L S
TECHNICAL FIELD The present invention relates to the development and differentiation of cells in a mammalian immune system. More particularly, the invention provides culture conditions for the in vitro maturation of precursor B cells. This is a valuable invention because it defines a method to induce development of antibody producing mature B-cells from early precursor cells.
BACKGROUND OF THE INVENTION
Significant health problems are faced in circumstance where immune function is compromised, such as where chemotherapy has destroyed a patient's peripheral blood cells, in radiation sickness, in organ transplant patients and in patients with a compromised immune system where Ig levels are subnormal, including patients with primary and secondary immune deficiencies, and premature infants that are highly susceptible to infections. These patients suffer problems from chronic and acute infections often caused by environmental pathogens found in many hospital settings. Supplementation of a compromised immune system with mature B cells will often restore at least partial normal immune system growth, differentiation and regulation.
Thus there is a need for a method to supplement a compromised immune system with mature B cells.
SUMMARY OF THE INVENTION
The present invention fills this need by providing for an in vitro method of inducing differentiation of precursor B cells (pre-B cells) to mature Immunoglobulin (Ig) -secreting B cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4 and a contact mediated signal provided by optimally activated CD4+ T cells.
The contact mediated signal is generally provided by incubating optimally activated CD4+ T cells, i.e., CD4+ T cells which have been activated for from 2-3 days, with the precursor B cells and the IL-4. The contact mediated signal can also be provided by cell membranes from optimally activated CD4+ T cells. The medium may also contain IL-7.
The present invention further provides for an in vitro method of inducing differentiation of precursor B cells (pre-B cells) to mature Immunoglobulin (Ig) -secreting B cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4, IL-7 and a contact mediated signal provided by non-optimally activated CD4+ T cells. An example of a non-optimally activated CD4+ T cell is a CD4+ T cell which has been activated for from 4-6 days.
The resulting mature B cells may be introduced into a host and in certain embodiments may be derived from the same host.
The present invention further provides for methods of reconstituting an impaired immune system of a human comprising the steps of: (a) isolating precursor B cells from a human; (b) maturing the precursor B cells to maturity by contacting the precursor B cells in an aqueous medium with an amount of IL-4 and contact mediated signal provided by optimally activated CD4+ T cells or membranes from an optimally activated CD4+ T cell effective to mature the precursor B cells; and (c) administering the mature B cells of step (b) to a human.
Alternatively, if non-optimally activated CD4+ T cells are used then IL-7 is added to the aqueous medium so as to produce mature Ig-secrering B cells.
The present invention further provides for in vivo methods of maturing precursor B cells in mammals by administering an effective amount of IL-4 and IL-7 sufficient to mature precursor B cells into mature B cells. The preferred mode involves human IL-4 and human and IL-7.
The present invention also provides a biological screening method to define the co-stimulating components needed to support growth and differentiation of early precursor B cells. The present
invention has allowed identification of the importance of activated CD4+ T cells or their membranes, in human B cell development. This in vitro assay can also be used to identify the factors and genes encoding co-stimulatory components.
The invention further discloses the therapeutic utility of IL-7 when combined with IL-4 for the in vivo maturation of pre-B cells.
DETAILED DESCRIPTION
Deficient humoral immunity is a problem in a number of situations, such as after bone marrow [BM] transplantation and in newborns, especially premature newborns, whose major cause of death are bacterial infections. In addition, agammaglobulinemias due to genetic defects can cause life long susceptibility to infections. We have now established a short-term culture system to induce growth and differentiation of plasma cells from pre-B cells in vitro. In addition, the clinical use of IL-4 and IL-7 are disclosed.
Mature resting B cells differentiate into Immunoglobulin [Ig] secreting cells and undergo Ig isotype switching in response to surface IgM [slgM] mediated signals in the presence of a contact mediated signal which is provided by CD4+ T cells via soluble and membrane bound factors. Cytokines are thought essential in B cell proliferation and differentiation, as well as in isotype switching. Under in vitro conditions, IL-4 is known to induce IgG4 and IgE switching, but additional signals provided by CD4+ T cells are required. Several other cytokines, such as IL-6, tumor necrosis factor (TNF)-α, TGF-β, IFN-α, and IFN-γ, are known to modulate IL-4-induced IgE synthesis in mature B cells. TGF-β also induces IgA switching.
Little is known about signal requirements for human pre-B cells to differentiate into mature B cells or into Ig secreting plasma cells. This is largely due to lack of knowledge of culture conditions that would induce pre-B cell differentiation in vitro. There has been successful work with murine B cell precursors which have been successfully cultured using the Whitlock-Witte culture system [Whitlock & Witte, Proc. Natl. Acad. Sci. 79: 3608-3602 (1982)].
The essential requirement of the Whitlock-Witte culture is the establishment of an adherent stromal cell microenvironment mimicking the bone marrow. Successful long-term culture of murine B cell precursors is dependent on the presence of stromal cells. In addition, murine pre-B cells were shown to undergo isotype switching and to differentiate into Ig secreting plasma cells when co-cultured with dendritic cells and activated T cells [Spalding & Griffen, Cell 44: 507-515 (1986)]. However, these culture systems have not been successful when human pre-B cells are studied.
Pre-B cells are classically characterized by lack of surface IgM (slgM") expression. Human pre-B cells were recently shown to spontaneously differentiate into IgM+ cells when cultured in RPMI + 10% fetal calf serum in the absence of exogenous growth factors or cytokines, but no differentiation into Ig-secreting cells in these cultures was detected [Villablanca et al. }. Exp. Med. 172: 325-334 (1990)]. More recently, it was demonstrated that immature CD10+, CD19+, sIgM+ B cells derived from fetal spleen or bone marrow (BM) are able to undergo isotype switching and differentiate into Ig-secreting cells in response to IL-4 in the presence of anti-CD40 monoclonal antibodies (mAb) or CD4+ T cells [Punnonen et al. }. Immunol. 148: 3398-3404 (1992)]. However, in those culture conditions slgM" pre-B cells failed to differentiate into Ig- secreting cells.
The present invention provides culture conditions permitting maturation of human pre-B cells. The work demonstrates that significant production of IgM, total IgG, IgG4 and IgE is detected when highly purified human slgM", CD19+ pre-B cells are co-cultured with optimally activated cloned CD4+ T cells in the presence of IL-4. An optimally activated CD4+ T cell is a CD4+ T cell which is able to produce a contact mediated signal needed for human slgM", CD19+ pre-B cells to develop into mature Ig secreting B cells in the presence of IL-4. Generally, the CD4+ T cells which are used are obtained 2-3 days after activation. When CD4+ T cells are used 4-6 days after activation, no Ig synthesis by the B cells is observed. However, if IL-7 is added to a culture containing IL-4 and CD4+ T cells which have been obtained 4-6 days after activation, the human slgM", CD19+ pre-B cells do develop
into Ig secreting mature B cells. This is distinguished from earlier work (Punnonen et al, 1992, supra) which disclosed that sIgM+ fetal BM B cells underwent isotype switching and differentiation into Ig secreting cells in response to CD4+ T cells and IL-4 without IL-7.
Membrane preparations of activated CD4+ T cell clones will also induce IgM and IgG synthesis by pre-B cells in the presence of IL-4 indicating that the co-stimulatory signal required in pre-B cell differentiation is in a membrane-bound form.
Precursor B cells are surface IgM" and CD19+. Classical definition of pre-B cells is that they have IgM in their cytoplasm (μ). By comparison, mature B cells are defined as expressing surface IgM and CD19". Pre-B cells can be obtained from bone marrow of either adults or fetuses.
In brief, pre-B cells are obtained from mammalian, e.g. human, bone marrow (BM). The marrow cells are extracted from the mammalian source using conventional techniques. These include extraction by needle or by surgical removal of bone material.
Details of obtaining bone marrow aspirate from a human patient are described in U.S. Patent Nos. 4,481,946 and 4,486,188. In brief prior to insertion of the needles into the bone marrow cavity, the cavity is washed with an anti-coagulation bath, e.g., heparin (2000 units). The bath comprises an intravenous solution (an isotonic saline electrolyte solution containing 4 units /cc heparin) which is introduced from a drip chamber by opening aspirator valves. Needles are inserted into the bone marrow cavity, and valve adjustments allow the entry of solution from the drip chamber followed by aspiration of marrow inducing the flow of marrow and sinusoidal blood.
The marrow cells are diluted with physiologically compatible buffer containing nutrients. Diluents include phosphate buffered saline (PBS) and RPMI-1640 from JRH Biosciences, Lenexa, KS which is preferred. The cells are repeatedly washed using low speed centrifugation. Red blood cells are lysed by osmotic shock using a hypotonic buffer solution. A preferred buffer and conditions are Tris-
buffered 0.83% NH4CI (pH 7.2) at room temperature for two minutes, after which the cells are washed twice. The intact cells are finally counted and resuspended in Yssel's medium [Yssel et al. }. Immunol. Methods, 72: 219 (1984)] supplemented with 10% fetal calf serum (FCS). Table 1 provides Yssel's medium.
TABLE 1 YSSEL'S MEDIUM
1. Iscove's modified Dulbecco's Medium (IMDM (JRH Biosciences 51-47178, 500 ml) (w/1-glutamine, w/25 mM HEPES, w/ Alpha thioglycerol).
2. Bovine serum albumin (Sigma, A2153 or <0.1ng/mg endotoxin detectable (Sigma A3675) to final concentration of 0.25% (w/v).
3. 2-aminoethanol (Ethanolamine: Sigma E0135, 100 ml) to final concentration of 1.8 μg per liter. 4. Transferrin (Apo form) (Pierce) liquid or powder final concentration 20 μg/ml.
5. Insulin (Sigma from bovine pancreas 1-5500, 1 gram) to final concentration of 5 μg/ml (dissolve insulin first in 5 ml 0.01N HC1 and add this to the medium). 6. Linoleic acid (Sigma L1376) to final concentration of 2 μg/ml.
7. Oleic acid (Sigma 03879) to final concentration of 2 μg/ml (Stock linoleic and oleic acid should be stored at -20°C under nitrogen to prevent oxidation of the unsarurated bond; make glass ampoules containing 5 mg of linoleic & 5 mg of oleic acid. For each preparation, dissolve the fatty acids in ethanol (100 μl) and add this mixture to the medium.
8. Palmitic acid (Sigma P-5917) to final concentration of 2 μg/ml [stock of palmitic acid in ethanol (20 mg/ml) and add the right concentration] (store at 4°C). 9. Penicillin / streptomycin (TRH cat. nr. 59-60277P, 100 ml) 5 ml in 500 ml.
From the remaining cells, the pre-B cells are obtained. The pre-B cells are isolated by monoclonal antibodies specific for pre-B cells. The desired slgM", CD19+ pre-B cells are then sorted using a fluorescence activated cell sorter (FACS) or magnetic beads according to standard procedures. The pre-B cells may be crudely enriched using a ficoll density gradient where the pre-B cells are separated from red blood cells
and granulocytes on a density gradient (1.077 gm/ml) spun at 800 x g for 20 minutes. The pre-B cells will be found at the interface. Alternatively, one can take advantage of the fact that the pre-B cells do not carry the following epitope markers CD3, CD4, CD8, CD14, CD33 or slgM. By passing the cells through binding columns which target these markers, the desired pre-B cells can be isolated from undesired cells. Finally the pre-B cells are isolated from the heterogeneous population of bone marrow cells using immunoaffinity methods which specifically target unique pre-B cell surface epitopes. Such epitopes include CD19 and CD10. Conditions which permit cell survival and binding between antibodies and the cells are known and a general reference explaining this art is Punnonen et al, }. Immunol. 148: 3398-3404 (1992).
The pre-B cells are cultured in the presence of optimally activated CD4+ T cells or membranes obtained from the activated T cells. The
CD4+ T cells are cloned from activated mammalian (human) peripheral blood cells (PBC). In brief, peripheral blood cells are obtained from standard blood drawing techniques. The cells are then activated by mitogenic lectins such as phytohemagglutinin (PHA), Concanavalin A (Con A), soluble antigens such as tetanus toxoid, alloantigens expressed in allogenic PBC, or Epstein Barr Virus (EBV) transformed in B cells. Next the cells are cloned according to standard procedures in the presence of a mixture of irradiated PBC and EBV transformed B cell line cells and PHA as described by Spits et al, }. Immunol. 128: 95-99 (1982).
The maturation of the pre-B cells takes place in the presence of contact mediated signal provided by optimally activated CD4+ T cells and IL-4. IL-7 can also be added to enhance differentiation of the pre-B cells into Ig-secreting cells. However, if the CD4+ T cells are not optimally activated, i.e., they have been activated for more than 4 days, then IL-7 must be added to the culture medium in order for the pre-B cells to differentiate into Ig-secreting cells. Both cytokines are available through conventional recombinant expression systems. For example, a suitable expression system for IL-4 is described in U.S. Pat. No. 5,017,691. The cloning and expression of IL-7 has been described by Goodwin
PNAS 86: 302-306 (1989) and Lupton, et al, }. Immunol. 3592-3601 (1990). Alternatively, these cytokines can be purchased from commercial vendors such as R & D Systems, Inc. Minneapolis, MN.
Maturation of the B cells can be monitored using a number of standard procedures. For example, one can measure the production of IgM, IgG, IgG4, IgE, or IgA using enzyme immunoassays. In brief, these methods involve standard immunoassays for the secretion of the several Ig classes known to be produced by mature B cells. Alternatively, surface molecules may be detected using analytical FACS methods.
The in vitro maturation of pre-B cells permits the re-infusion into a patient, preferably the same patient from which the pre-B cells originated. The cells are harvested from the nutrient medium and resuspended into a physiologically compatible medium such as standard isotonic infusion fluids. The cells are then re-infused directly into the patient using conventional intravenous equipment. Procedures follow those for autologous bone marrow transplantation, e.g., reviewed in Bombik, B.M., Strategy of Autologous Bone Marrow Transplantation, in Autologous Bone Marrow Transplantation and Solid Tumors, J.G. McVie, O. Dalesio and IE. Smith, eds., pp. 13-18 (1984); and Autologous Bone Marrow Transplantation, Dickey, Spitzer, and Jagannath (Eds.), The University of Texas, M.D. Anderson Hospital and Tumor Institute at Houston (1987).
For infusion, the total number of mature B cells are preferably between 1-8 x 106 cells per kilogram of weight. The total liquid being infused should be between .75 and 1.5 liters for a mammal of 70 kg. Infusion of the entire mixture is typically carried out via a central venous catheter. As an optional step, the patient may receive supplemental therapy with a pharmaceutical preparation comprising the selected antibiotics.
From a practical perspective, one seeks to achieve maximum restoration of antibody producing B cells. Accordingly, a maximum number of B cells are desired for infusion. Pre-B cells represent approximately 1% of the cells in adult BM. Typically, no more than
5 x 108 cells can be isolated from a standard BM sample. By growing the pre-B cells under present culture conditions the cells can be increased 3 to 6 fold after 7 days. Thus, 3 x 109 cells will be available for infusion
from a single BM aspiration. The level of antibody production and/or B cell numbers are monitored in order to re-administer additional B cells as necessary.
Alternatively, there are patients which have a B cell deficiency who will benefit from the co-administration of IL-4 and IL-7. Such patients include those with hypogammaglobulinemias, newborns, patients after BM transplantations, or cancer after heavy chemo- or radiation therapy. Both cytokines are co-administered to these patients either simultaneously or in succession. For an average patient in need of in vivo maturation of B cells, a dosage range of about 0.5 to about 10 and preferably 1 to 5 μg/kg body weight of both IL-4 and IL-7 is co- administered on a daily basis until the level of B cells approaches normal.
EXAMPLES
The present invention can be illustrated by the following, non- limiting Examples. Unless otherwise specified, percentages given below for solids in solid mixtures, liquids in liquids, and solids in liquids are on a wt/wt, vol/vol and wt/vol basis, respectively.
1. Method for maturing B cells from precursor cells. A. Reagents.
The following reagents were used to isolate and mature human pre-B cells. Purified human recombinant IL-4 was provided by Schering-Plough Research (Kenilworth, NJ). Recombinant IL-7 was obtained from R & D Systems Inc. (Minneapolis, MN). Phycoerythrine (PE)-conjugated mAbs against CD19 as well as isotype control antibodies with irrelevant specifications, were obtained from Becton Dickinson (Mountain View, CA). FITC-conjugated anti-IgM mAb was obtained from Nordic Immunological Laboratories (Tilburg, the Netherlands).
B. Cell preparations.
Human fetal bone marrow (BM) samples were obtained from fetuses varying from 16 to 24 weeks of gestation. BM cells were obtained by flushing RPMI-1640 0RH Biosciences, Lenexa, KS) with a syringe into
the intramedullary cavities of the long bones. The cells were washed twice. Red blood cells were lysed by exposure to 2 ml of Tris-buffered 0.83% NH4CI (pH 7.2) at room temperature for two minutes, after which the cells were washed twice. The cells were finally counted and resuspended in Yssel's medium [Yssel et al. }. Immunol. Methods, 72 : 219 (1984)] supplemented with 10% fetal calf serum [FCS].
B cell precursors were obtained from fetal BM using fluorescence- activated cell sorter, FACStar Plus® (Becton Dickinson). BM cells were first incubated with CD19-PE and slgM-FITC for 30 min at 4°C. FTTC- and PE-conjugated mAb with irrelevant specificities were used as negative controls. The cells were washed twice with PBS. Cells with the light scatter characteristics of lymphocytes were gated and the cells were sorted on the basis of fluorescence stainings. Re-analysis of the sorted cells indicated 97-100% purities.
C. Culture conditions.
The cells obtained were cultured in round-bottomed 96-well plates (Linbro, McLean, VA; Cat. No. 76-013-05) at 37°C in a humidified atmosphere containing 5% CO2 in 0.2 ml Yssel's medium supplemented with 10% FCS. The cells were cultured at a concentration of 5000 cells/well. All cultures were performed in triplicate. In co-culture experiments, the human CD4+ T cell clone B21 [Roncarolo et al, f. Exp. Med. 167 : 1523 (1988) and Vieira et. al, Proc. Natl. Acad. Sci, U.S.A. 88 : 1172-1176 (1991)] was added at the onset of the cultures at 5000 cells/well. B21 cells were obtained 2 days or 4-6 days after they had been activated by feeder cell mixture and PHA at 0.1 μg/ml as described by Gascan et. al, J. Exp. Med. 173 : 747-750 (1991) and Gascan et al, Eur. }. Immunol, 22 : 1133-1141 (1992). All cytokines used were added at the onset of the culture. IL-4 and IL-7 were added at a concentration of 8 μg/ml and 15 μg/ml, respectively.
D. Measurement of Ig production.
IgM, total IgG, IgA and IgE secretion were determined by ELISA as described previously by Pene et al, Proc. Natl. Acad. Sci, U.S.A. 85 : 8166- 8170 (1988) and Pene et al, }. Immunol. 141 : 1218-1224 (1988). IgG4
secretion was determined by ELISA as described by Punnonen et al, J. Immunology, 148 : 3398-3404 (1992). The sensitivities of IgM, total IgG, and IgA ELISAs were 0.5-1 ng/ml, and the sensitivities of IgG4 and IgE ELISAs were 0.2 ng/ml.
E. Results.
The highly purified pre-B cells were co-cultured in the presence of activated CD4+ T cells, IL-4 and/or IL-7. Significant production of IgM, total IgG, IgG4, and IgE in pre-B cell cultures was detected. Kinetic studies indicated that detectable levels of IgM and IgG in the supernatants of these cultures appeared at day 7, while IgE was detected at day 10. When the T cells were used 4-6 days after they had been activated, IL-7 was a specific requirement together with IL-4 of pre-B cells for maturation. When the T cells were used 2-3 days after activation, they were competent to mature the pre-B cells with only the addition of IL-4 and without the addition of IL-7.
To ensure that the production of immunoglobulins was not an artifact attributed to contaminating mature B cells, the production of Ig was measured at decreasing cell numbers. Ig production in pre-B cell cultures was detected at cell numbers as low as 100 B cells/well. Because Ig production was detected using such low pre-B cell numbers, and no slgM"1" cells among sorted slgM" pre-B cells could be detected by FACS- analysis, the possibility of contaminating sIgM+ B cells as the cause of Ig synthesis in our pre-B cell cultures can be excluded.
In addition, the fact that the mature sIgM+, CD19+ B cells produce Ig when co-cultured with IL-4 and CD4+ cloned T cells 4-6 days after the T cells had been activated whereas slgM", CD19+ pre-B cells failed to do so also strongly argues against contaminating sIgM+ cells as the cause of Ig synthesis detected, and indicates that the signals required for slgM"1" immature B cells to differentiate into Ig-secreting cells are not sufficient to mediate slgM" pre-B cell differentiation.
Supernatants of activated CD4+ T cell clone failed to induce pre-B cell differentiation regardless of whether IL-7 was present or not, suggesting that the co-stimulatory signal(s) provided by the T cells was
in membrane-bound form. The effect of T cell membranes on pre-B cell differentiation was studied to further investigate this possibility.
A CD4+ T cell clone was activated for two days by ConA, and the cells were disrupted and membrane preparations were prepared as described by Gascan et al, Eur. f. Immunol, 22 : 1133-1141(1992). The data indicate that these membrane preparations of CD4+ T cells induced IgM and IgG synthesis by pre-B cells in the presence of IL-4, indicating that the co-stimulatory signal required in pre-B cell differentiations, indeed, is in a membrane-bound form. This implies that the present culture system also can be used as a screening method to identify T-cell membrane associated molecules and the genes encoding these molecules.
2. Method for treating patients with mature B cells.
For a patient suffering from humoral immunodeficiency, an infusion of self-mature B cells is therapeutically beneficial. A bone marrow extract is obtained from the patient by aspiration. Pre-B cells are isolated from the marrow using the antibodies and cell sorting procedures provided in Example 1. The purified pre-B cells are then cultured and matured to antibody producing B cells according to the methods of Example 1. Mature antibody producing B cells are then harvested, suspended in physiological saline solution and re-infused. The number of circulating mature B cells and antibody production are then monitored using conventional techniques.
Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be recognized that certain changes and modifications may be practiced within the scope of the claims.
Claims
1. An in vitro method of inducing differentiation of precursor B cells to immunoglobulin (Ig)-secreting cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4 and a contact mediated signal provided by optimally activated CD4+ T cells.
2. The method of claim 1 wherein the aqueous medium contains activated CD4+ T cells which have been activated for less than 4 days.
3. The method of claim 1 wherein the aqueous medium contains membranes of activated CD4+ T, wherein said activated CD4+ T cells have been activated for less than 4 days.
4. The method of claims 1, 2 or 3 wherein the activated CD4+ T cells have been activated for from 2 to 3 days.
5. The method of claims 1, 2, or 3 wherein IL-7 is added to the aqueous medium.
6. An in vitro method of inducing differentiation of precursor B cells to immunoglobulin (Ig)-secreting cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4, IL-7 and a contact mediated signal provided by non-optimally activated CD4+ T cells.
7. The method of claim 6 wherein the aqueous medium contains activated CD4+ T cells which have been activated for 4-6 days.
8. The method of claim 6 wherein the aqueous medium contains membranes of activated CD4+ T, wherein said activated CD4+ T cells have been activated for 4-6 days. .
9. The use of IL-4 with a contact mediated signal provided by optimally activated CD4+ T cells to induce the differentiation of pre-B cells into Ig-secreting cells.
10. The use of IL-4 and IL-7 with a contact mediated signal provided by non-optimally activated CD4+ T cells to induce the differentiation of pre-B cells into Ig-secreting cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48072/93A AU4807293A (en) | 1992-08-21 | 1993-08-18 | Methods for maturing precursor b cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93346192A | 1992-08-21 | 1992-08-21 | |
US07/933,461 | 1992-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994004658A1 true WO1994004658A1 (en) | 1994-03-03 |
Family
ID=25464008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/007644 WO1994004658A1 (en) | 1992-08-21 | 1993-08-18 | Methods for maturing precursor b cells |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4807293A (en) |
WO (1) | WO1994004658A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2301114A (en) * | 1995-05-24 | 1996-11-27 | Bradley Michael John Stringer | Method for controlling differentiation of precursor cells |
US6004812A (en) * | 1994-12-01 | 1999-12-21 | Beth Israel Medical Center, Inc. | In-vitro T-lymphopoiesis system |
-
1993
- 1993-08-18 AU AU48072/93A patent/AU4807293A/en not_active Abandoned
- 1993-08-18 WO PCT/US1993/007644 patent/WO1994004658A1/en active Application Filing
Non-Patent Citations (5)
Title |
---|
BLOOD, vol. 78, no. 9, 1991, pages 2229 - 2238 * |
CHEMICAL ABSTRACTS, vol. 116, no. 3, 20 January 1992, Columbus, Ohio, US; abstract no. 19517j, S. SAELAND ET AL.: "INTERLEUKIN-7 INDUCES THE PROLIFERATION OF NORMAL HUMAN B-CELL PRECURSORS." page 440; * |
CHEMICAL ABSTRACTS, vol. 117, no. 1, 6 July 1992, Columbus, Ohio, US; abstract no. 5919a, H. GASCAN ET AL.: "MEMBRANES OF ACTIVATED CD4+ T CELLS EXPRESSING T CELL RECEPTOR (TcR) ALPHA BETA OR TcR GAMMA DELTA INDUCE IgE SYNTHESIS BY HUMAN B CELLS IN THE PRESENCE OF INTERLEUKIN-4." page 622; * |
EUR. J. IMMUNOL., vol. 22, no. 5, 1992, pages 1133 - 1141 * |
J. PUNNONEN ET AL.: "INDUCTION OF ISOTYPE SWITCHING AND Ig PRODUCTION BY CD5+ AND CD10+ HUMAN FETAL B CELLS.", JOURNAL OF IMMUNOLOGY., vol. 148, no. 11, 1 June 1992 (1992-06-01), BALTIMORE US, pages 3398 - 3404 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004812A (en) * | 1994-12-01 | 1999-12-21 | Beth Israel Medical Center, Inc. | In-vitro T-lymphopoiesis system |
GB2301114A (en) * | 1995-05-24 | 1996-11-27 | Bradley Michael John Stringer | Method for controlling differentiation of precursor cells |
Also Published As
Publication number | Publication date |
---|---|
AU4807293A (en) | 1994-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5866115A (en) | Process for preparing dendritic cells, cells thus produced and containers for carrying out this process | |
US9095538B2 (en) | Cancer vaccines and vaccination methods | |
EP0633930B1 (en) | In vitro generation of human dendritic cells | |
US20230257709A1 (en) | New immunoregulatory cells and methods for their production | |
CA2192655A1 (en) | Methods for in vivo t cell activation by antigen-pulsed dendritic cells | |
EP0925356B1 (en) | New antigen presenting cells, a process for preparing the same and their use as cellular vaccines | |
JP3541140B2 (en) | Method for activating natural killer (NK) cells and means for implementing the method | |
WO2003039232A2 (en) | Endothelial cell derived hemotopoietic growth factor | |
Curti et al. | Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy | |
AU7867400A (en) | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells | |
CA2977754A1 (en) | Compositions and methods of treating multiple myeloma | |
CN115044553B (en) | mTOR-targeted tolerant dendritic cell and preparation method and application thereof | |
WO1994004658A1 (en) | Methods for maturing precursor b cells | |
Koyama et al. | Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumor cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma | |
WO2002040647A1 (en) | Method of establishing cultures of human dendritic cells and use thereof | |
KR101440102B1 (en) | Manufacturing method of strong antigen-presenting cells using hydrogel coating and electroporation | |
CN114790445B (en) | Preparation method and application of CD4-CD8-NKT cell | |
CN115232789B (en) | Method for preparing cytokine-induced killer cells by using Daudi cell membrane capsules | |
CA2252505C (en) | New antigen presenting cells, a process for preparing the same and their use as cellular vaccines | |
CN114591908A (en) | Stimulating factor for inducing Tregs to obtain embryo antigen specificity iTregs, culture medium, method and application | |
Burgoyne | Improved dendritic cell therapy for cancer by enhancing in vivo lymph node migration using a novel chemokine-based sorting method | |
CN116836924A (en) | Method for culturing dendritic cells and application thereof | |
CN115537398A (en) | Method for large-scale preparation of GMP-grade mature DC cells | |
EP1032651A1 (en) | INDUCIBLE CELLULAR IMMUNITY THROUGH ACTIVATION OF Th1 AND SUPPRESSION OF Th2 RESPONSES BY MACROPHAGES | |
KR20010046514A (en) | Differentiation of human Dendritic cells from peripheral blood monocytes and establishment of Blood Savings Bank |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR BY CA CZ FI HU JP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |